Gilead's 2nd positive Phase III sets up early FDA submission for Quad
This article was originally published in Scrip
Positive top-line results reported this week from a second Phase III study of Gilead Sciences' once-daily, fixed-dose, four-in-one HIV pill, known as Quad (emtricitabine, tenofovir disoproxil fumarate, evitegravir and cobicsta), has given the biotech giant the confidence it needed to move its timeline up for submitting a new drug application to the US FDA, which the company said will now occur before the end of this year rather than early next year.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.